Table 4: Treatment of patients with disease progression.

Patient Origin Risk group (AFIP-Miettinen8) Adjuvant Imatinib (months) Recurrence time (months) Recurrence site Treatment for progression Follow-up (months) Outcome
1) Small intestine Intermediate No 40 Local recurrence Surgical resection and imatinib 60 AWD
2) Small intestine High 24 24 Peritoneal dissemination Surgical resection and imatinib 36 AD
3) Small intestine High 24 28 Peritoneal dissemination Surgical resection and imatinib 48 AD
4) Small intestine Intermediate 36 40 Local recurrence Surgical resection and imatinib 55 AWD
5) Small intestine High 24 36 Local recurrence Surgical resection and imatinib 60 AD
6) Stomach High 18 18 Liver Imatinib 41 DD

AWD: Alive without disease; DD: Died of disease; AD: Alive with disease.